Discovery and lead identification of quinazoline-based BRD4 inhibitors.

Bioorg Med Chem Lett

National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States. Electronic address:

Published: November 2018

AI Article Synopsis

Article Abstract

A new series of quinazoline-based analogs as potent bromodomain-containing protein 4 (BRD4) inhibitors is described. The structure-activity relationships on 2- and 4-position of quinazoline ring, and the substitution at 6-position that mimic the acetylated lysine are discussed. A co-crystallized structure of 48 (CN750) with BRD4 (BD1) including key inhibitor-protein interactions is also highlighted. Together with preliminary rodent pharmacokinetic results, a new lead (65, CN427) is identified which is suitable for further lead optimization.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392372PMC
http://dx.doi.org/10.1016/j.bmcl.2018.08.039DOI Listing

Publication Analysis

Top Keywords

brd4 inhibitors
8
discovery lead
4
lead identification
4
identification quinazoline-based
4
quinazoline-based brd4
4
inhibitors series
4
series quinazoline-based
4
quinazoline-based analogs
4
analogs potent
4
potent bromodomain-containing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!